DRTS Stock Overview
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alpha Tau Medical Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.49 |
| 52 Week High | US$4.80 |
| 52 Week Low | US$2.41 |
| Beta | 0.71 |
| 1 Month Change | -14.73% |
| 3 Month Change | -21.08% |
| 1 Year Change | -15.88% |
| 3 Year Change | -74.41% |
| 5 Year Change | n/a |
| Change since IPO | -75.35% |
Recent News & Updates
Shareholder Returns
| DRTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.4% | 1.8% | 1.2% |
| 1Y | -15.9% | -0.5% | 24.9% |
Price Volatility
| DRTS volatility | |
|---|---|
| DRTS Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: DRTS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 121 | Uzi Sofer | www.alphatau.com |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company’s Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. Fundamentals Summary
| DRTS fundamental statistics | |
|---|---|
| Market cap | US$174.18m |
| Earnings (TTM) | -US$29.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs DRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRTS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.16m |
| Earnings | -US$29.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.6% |
How did DRTS perform over the long term?
See historical performance and comparison